MarketCapExport financials
USANA Health Sciences (USNA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
USANA Health Sciences Balance Sheet 2026-2009 | USNA
Brief overview of USANA Health Sciences's assets and capital
The balance sheet is assessed across five available annual reports spanning 2018 to 2026.
The balance sheet expanded from $554.5 million to $742.9 million. Growth of +34% and CAGR of 3.7% look measured and sustainable.
Growth in the asset base was not matched by liabilities: +34% versus -4.1%. The balance sheet moved in a more conservative direction.
The equity ratio reached 71.8% from 70.5%. A high capital share reduces dependence on liabilities.
The balance sheet holds more cash than interest-bearing debt; net debt is -$140.4 million, indicating minimal leverage.
Cash represents 21.3% of assets versus 38.7% initially, showing how the immediate liquidity reserve changed.
Retained earnings are $465.7 million versus $329.5 million initially. The direction shows how results contributed to equity.
Overall picture
USANA Health Sciences has a solid balance sheet cushion. Capital and liquidity support development without excessive reliance on debt.
Annual Balance Sheet USANA Health Sciences
| 2026 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-140 M | -166 M | -318 M | -274 M | - | - | -235 M | -214 M | -247 M | -143 M | -111 M | - | -137 M | -70.8 M | -24.2 M | - | - |
Long Term Debt |
12.3 M | 10.2 M | 5.14 M | 7.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
5.65 M | 6.01 M | 7.28 M | 6.89 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 29.1 M | 14.6 M | 14.9 M | 11 M | 11.7 M | - | 12 M | 11 M | 10.8 M | - | - |
Total Current Liabilities |
129 M | 140 M | 119 M | 144 M | 168 M | - | 136 M | 149 M | 141 M | 138 M | 109 M | - | 95.9 M | 70.8 M | 59.7 M | - | - |
Total Liabilities |
157 M | 162 M | 136 M | - | - | - | 165 M | 163 M | 156 M | 142 M | 120 M | - | 108 M | 81.8 M | 69.8 M | - | - |
Deferred Revenue |
10.6 M | 12 M | 13.9 M | 20.9 M | 16 M | - | 2.73 M | 2.65 M | 17 M | 17.6 M | 15.7 M | - | 16.1 M | 15.6 M | 1.71 M | - | - |
Retained Earnings |
466 M | 479 M | 445 M | 392 M | 383 M | - | 306 M | 330 M | 288 M | 215 M | 166 M | - | 200 M | 135 M | 90.2 M | - | - |
Total Assets |
743 M | 748 M | 633 M | 597 M | 641 M | - | 517 M | 554 M | 519 M | 423 M | 351 M | - | 368 M | 267 M | 217 M | - | - |
Cash and Cash Equivalents |
158 M | 182 M | 330 M | 288 M | 312 M | - | 235 M | 214 M | 247 M | 176 M | 111 M | - | 137 M | 70.8 M | 50.4 M | 13.7 M | 13.3 M |
Book Value |
586 M | 586 M | 497 M | 597 M | 641 M | - | 352 M | 391 M | 363 M | 281 M | 230 M | - | 261 M | 186 M | 147 M | - | - |
Total Shareholders Equity |
533 M | 532 M | 497 M | 434 M | 442 M | - | 352 M | 391 M | 363 M | 325 M | 230 M | - | 261 M | 186 M | 174 M | 74.4 M | 31.8 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet USANA Health Sciences
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | 10.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.3 M | 12.6 M | 12.6 M | 11.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
157 M | 144 M | 162 M | 145 M | 149 M | 163 M | 162 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | 12 M | - | - | - | - | - | - | - | - | - | - | - | 19.6 M | - | - | - | 16 M | - | - | - | - | - | - | - | 13.9 M | - | - | - | 2.65 M | - | - | - | 3.06 M | - | - | - | 21.5 M | - | - | - | 15.7 M | - | - | - | - | - | - | - | 16.1 M | - | - | - | 15.6 M | - | - | - | 10.1 M | - | - | - |
Retained Earnings |
466 M | 473 M | 479 M | 467 M | 474 M | 478 M | 479 M | 474 M | 464 M | 453 M | 445 M | 428 M | 427 M | 410 M | 392 M | 379 M | 364 M | 345 M | 383 M | 350 M | 366 M | 353 M | - | 343 M | 313 M | 285 M | 306 M | 306 M | 306 M | 306 M | 330 M | 330 M | 330 M | 330 M | 288 M | 288 M | 288 M | 288 M | 265 M | 265 M | 265 M | 265 M | 166 M | 237 M | 212 M | 186 M | - | 156 M | 197 M | 217 M | 200 M | 200 M | 200 M | 200 M | 135 M | 135 M | 135 M | 135 M | 119 M | 119 M | 119 M | 119 M |
Total Assets |
743 M | 739 M | 748 M | 727 M | 735 M | 747 M | 748 M | 671 M | 631 M | 629 M | 633 M | 601 M | 603 M | 606 M | 597 M | 556 M | 558 M | 573 M | 641 M | 579 M | 591 M | 585 M | - | 578 M | 512 M | 474 M | 517 M | 517 M | 517 M | 517 M | 554 M | 554 M | 554 M | 554 M | 519 M | 519 M | 519 M | 519 M | 471 M | 471 M | 471 M | 471 M | 351 M | 439 M | 409 M | 375 M | - | 317 M | 355 M | 371 M | 368 M | 368 M | 368 M | 368 M | 267 M | 267 M | 267 M | 267 M | 244 M | 244 M | 244 M | 244 M |
Cash and Cash Equivalents |
154 M | 163 M | 333 M | 145 M | 151 M | 180 M | 182 M | 365 M | 332 M | 328 M | 330 M | 307 M | 300 M | 295 M | 288 M | 247 M | 230 M | 238 M | 312 M | 249 M | 265 M | 257 M | - | 278 M | 227 M | 194 M | 235 M | 235 M | 235 M | 235 M | 214 M | 214 M | 214 M | 214 M | 247 M | 247 M | 247 M | 247 M | 176 M | 176 M | 176 M | 176 M | 111 M | 174 M | 151 M | 129 M | - | 87.7 M | 118 M | 143 M | 137 M | 137 M | 137 M | 137 M | 70.8 M | 70.8 M | 70.8 M | 70.8 M | 50.4 M | 50.4 M | 50.4 M | 50.4 M |
Book Value |
586 M | 595 M | 586 M | 582 M | 586 M | 584 M | 586 M | 671 M | 631 M | 629 M | 633 M | 601 M | 603 M | 606 M | 597 M | 556 M | 558 M | 573 M | 641 M | 579 M | 591 M | 585 M | - | 578 M | 512 M | 474 M | 517 M | 517 M | 517 M | 517 M | 554 M | 554 M | 554 M | 554 M | 519 M | 519 M | 519 M | 519 M | 471 M | 471 M | 471 M | 471 M | 351 M | 439 M | 409 M | 375 M | - | 317 M | 355 M | 371 M | 368 M | 368 M | 368 M | 368 M | 267 M | 267 M | 267 M | 267 M | 244 M | 244 M | 244 M | 244 M |
Total Shareholders Equity |
532 M | 544 M | 434 M | 528 M | 531 M | 530 M | 532 M | 533 M | 512 M | 500 M | 497 M | 470 M | 469 M | 455 M | 434 M | 411 M | 404 M | 390 M | 442 M | 399 M | 419 M | 403 M | - | 389 M | 349 M | 318 M | 352 M | 352 M | 352 M | 352 M | 391 M | 391 M | 391 M | 391 M | 363 M | 363 M | 363 M | 363 M | 325 M | 325 M | 325 M | 325 M | 230 M | 313 M | 285 M | 253 M | - | 199 M | 254 M | 280 M | 261 M | 261 M | 261 M | 261 M | 186 M | 186 M | 186 M | 186 M | 174 M | 174 M | 174 M | 174 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of USANA Health Sciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Household products
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Coty
COTY
|
$ 3.05 | -5.13 % | $ 2.68 B |  USA |
 |
Dogness (International) Corporation
DOGZ
|
$ 0.77 | 5.11 % | $ 13.7 M |  China |
 |
e.l.f. Beauty
ELF
|
$ 113.78 | -0.84 % | $ 6.63 B | USA |
 |
Edgewell Personal Care Company
EPC
|
$ 26.98 | -4.39 % | $ 1.28 B | USA |
 |
Acme United Corporation
ACU
|
$ 63.2 | -0.6 % | $ 239 M | USA |
 |
Revlon
REV
|
- | -4.41 % | $ 212 M | USA |
 |
Mannatech, Incorporated
MTEX
|
$ 8.51 | 4.29 % | $ 16.2 M | USA |
 |
Colgate-Palmolive Company
CL
|
$ 93.4 | -1.21 % | $ 75.5 B | USA |
 |
Nature's Sunshine Products
NATR
|
$ 12.26 | -3.54 % | $ 221 M | USA |
 |
Nu Skin Enterprises
NUS
|
$ 4.76 | -4.51 % | $ 235 M | USA |
 |
Newell Brands
NWL
|
$ 5.56 | -2.11 % | $ 2.33 B | USA |
 |
Church & Dwight Co.
CHD
|
$ 105.0 | -0.91 % | $ 25.5 B | USA |
 |
The Procter & Gamble Company
PG
|
$ 156.84 | -1.61 % | $ 366 B | USA |
 |
The Estée Lauder Companies
EL
|
$ 103.66 | -2.32 % | $ 37.6 B | USA |
 |
United-Guardian
UG
|
$ 6.75 | -0.15 % | $ 31 M | USA |
 |
Unilever PLC
UL
|
$ 64.4 | -1.26 % | $ 141 B |  Britain |
 |
Hims & Hers Health
HIMS
|
$ 29.21 | -0.31 % | $ 6.57 B | USA |
 |
LifeVantage Corporation
LFVN
|
$ 5.95 | -0.34 % | $ 74.6 M | USA |
 |
Inter Parfums
IPAR
|
$ 113.2 | -2.33 % | $ 3.63 B | USA |
 |
Helen of Troy Limited
HELE
|
$ 28.38 | -3.54 % | $ 653 M |  Bermuda |
 |
Spectrum Brands Holdings
SPB
|
$ 78.96 | -0.7 % | $ 2.03 B | USA |
 |
The Clorox Company
CLX
|
$ 84.77 | -3.05 % | $ 10.5 B | USA |
 |
Kimberly-Clark Corporation
KMB
|
$ 106.64 | -1.56 % | $ 35.4 B | USA |
 |
Natura &Co Holding S.A.
NTCO
|
- | - | $ 9.02 B | - |